M&A Yearbook 2012

Report Summary

The Healthcare companies M&A Yearbook 2012 report provides comprehensive understanding and unprecedented access to the partnering and M&A deals and agreements entered into by the worlds leading healthcare companies during 2011.

• Bigpharma partnering activity during 2011
• Top partnering deals by value in 2011
• Top M&A deals by value in 2011
• Most active dealmakers 2011
• Comprehensive coverage of every deal announced in 2011

Description

The Partnering and M&A Yearbook 2012 report provides comprehensive understanding and unprecedented access to the partnering and M&A deals and agreements entered into by the worlds leading healthcare companies during 2011.

Using this report, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report allows you to view all the partnering, alliances and M&A deals announced worldwide.

Chapter 1 provides an introduction to the report, whilst chapters 2 and 3 provide an overview of partnering and M&A trends, respectively, in 2011. The key partnering and M&A deals of 2011 are reviewed, as well as forecasts for dealmaking in 2012.

Chapter 4 analyzes the most active dealmakers in partnering and M&A during 2011.

Chapter 5 provides an overview of the leading deals for 2011 by headline value. The chapter provides covers both partnering and M&A dealmaking during the year.

The main body of the report is provided in chapters 6, 7 and 8.

Chapter 6 provides an in-depth review of every bigpharma company provides the reader with a breakdown of that company’s dealmaking during 2011 by deal type, stage of development and therapy focus. Each company entry is supplemented with a comprehensive listing of deals entered into during 2011, complete with a hyperlink to the deal record online. Where a contract document is available, this may also be found in the deal record online as filed with the SEC.

Chapter 7 provides a comprehensive directory of partnering activity during 2011. The deals are listed by company A-Z, industry sector, deal type, stage of development and therapy focus, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.

Chapter 8 provides a comprehensive directory of partnering and M&A activity during 2011. The deals are listed by company A-Z, and industry sector, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of prospective partners’ negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.

In summary, the report provides the reader with the resources necessary to make research and understand the partnerships, alliances and M&A deals of 2011.

Benefits

Partnering and M&A Yearbook 2012 provides the reader with the following key benefits:

• In-depth understanding of dealmaking trends in 2011
• Comprehensive access to over 3,500 partnering and 600 M&A deals entered into by the world’s biopharma companies during 2011
• Detailed access to actual partnership and M&A deals and contracts entered into by the leading fifty bigpharma companies
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Scope                   

Partnering and M&A Yearbook 2012 is intended to provide the reader with an in-depth understanding and access to parthering and M&A trends and structure of deals entered into by leading companies worldwide.

Partnering and M&A Yearbook 2012 includes:

• Trends in dealmaking in the biopharma industry
• Analysis of partnering and M&A deal structure
• Comprehensive directory of partnering and M&A deals in 2011
• Links to online access to over 3,500 partnering and  600 M&A deals
• The leading partnering and M&A deals by value in 2011
• Most active partnering and M&A dealmakers during 2011

In Partnering and M&A Yearbook 2012, the partnering and M&A deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target
• Technology type

Each deal title links via Weblink to an online version of the deal record at Current Agreements and where available, the contract document, providing easy access to each contract document on demand.

Table Of Contents

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Overview of partnering activity in 2011
2.1. Introduction
2.2. Partnering activity in 2011
2.2.1. Partnering activity by volume
2.2.2. Partnering activity by deal dollars
2.3. Key partnering deals of 2011 – The top 10
2.3.1. Eli Lilly – Boehringer Ingelheim: Licensing, development and option agreement to co-market and co-develop insulin analogues
2.3.2. Lundbeck – Otsuka: Co-development and co-promotion agreement for up to five innovative psychiatric and neuroscience products
2.3.3. Eli Lilly – Amylin: Termination agreement for Bydureon (exenatide) once-weekly
2.3.4. Alios Biopharma – Vertex: Licensing agreement for ALS-2200 and ALS-2158
2.3.5. Astellas – Aveo Pharmaceuticals: Collaborative R&D and commercialisation agreement for tivozanib
2.3.6. Emergent BioSolutions – US Government: Contract service and supply agreement for BioThrax
2.3.7. Amgen – Micromet: Collaborative R&D agreement for BiTE antibodies against three undisclosed solid tumor targets
2.3.8.  Servier – mirage: Development agreement for miR-208 and miR-15/195 plus additional target
2.3.9.  Janssen Biotech – Pharmacyclics: Co-development, licensing and marketing agreement for PCI-32765
2.3.10. China Meheco: Supply agreement for drugs to Venezuela
2.4. Bigpharma partnering deals
2.5. Partnering deals by industry sector
2.6. Partnering deals by stage development
2.7. Partnering deals by deal type
2.8. Partnering deals by therapy area
2.9. Partnering deal terminations in 2011

Chapter 3 – Overview of M&A activity in 2011
3.1. Introduction
3.2. M&A deals of 2011
3.2.1. M&A activity by volume
3.2.2. M&A activity by deal dollars
3.3. Key M&A deals of 2011 – The top 10
3.3.1. Express Scripts – Medco Health Solutions: Acquisition agreement for Medco Health Solutions
3.3.2. Johnson & Johnson – Synthes: Acquisition agreement for Synthes
3.3.3. Takeda – Nycomed: Acquisition agreement for Nycomed
3.3.4. Gilead Sciences – Pharmasset: Acquisition agreement for Pharmasset
3.3.5. Danaher – Beckman Coulter: Acquisition agreement for Beckman Coulter
3.3.6. Teva – Cephalon: Acquisition agreement for Cephalon
3.3.7. DuPont – Danisco: Acquisition agreement for Danisco
3.3.8. Kinetic Concepts – Apax Partners: Acquisition agreement for Kinetic Concepts
3.3.9. PPD – Carlyle Group – Hellman & Friedman: Acquisition agreement for PPD
3.3.10. Thermo Fisher Scientific – Phadia: Acquisition agreement for Phadia
3.4. Bigpharma M&A deals of 2011
3.5. M&A deals by industry sector in 2011

Chapter 4 – Most active dealmakers in 2011
4.1. Introduction
4.2. Partnering – most active in 2011
4.3. M&A – most active in 2011

Chapter 5 – Top deals by value in 2011
5.1. Introduction
5.2. Top partnering deals in 2011
5.3. Top M&A deals in 2011

Chapter 6 – Bigpharma partnering in 2011
6.1. Introduction
6.2. Bigpharma partnering by industry sector
6.3. Bigpharma partnering by deal type
6.4. Bigpharma partnering by stage of development
6.5. Bigpharma partnering by therapy area
6.6. Bigpharma deal directory 2011
Abbott
Actavis
Alcon Labs
Allergan
Amgen
Apotex
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Cephalon
Chugai
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Forest Laboratories
Genzyme
Gilead Sciences
GlaxoSmithKline
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Mylan
Novartis
Novo Nordisk
Nycomed Pharma
Otsuka
Pfizer
Roche
Sanofi
Servier
Shionogi
Shire
Stada
Takeda
Teva
UCB
Warner Chilcott
Watson

Chapter 7 – Partnering directory 2011
7.1. Introduction
7.2. By company A-Z
7.3. By industry sector
Bigpharma
Pharmaceuticals
Biotechnology
Diagnostics
Drug delivery
Medical device
Consumer health
Specialty pharma
Generic pharma
Agricultural
Animal health
Research tools
Service company
Academic
Non-profit
Government
7.4. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
7.4. By deal type
Asset and product purchase
Assignment
Bigpharma out-licensing
Collaborative R&D
Co-development
Co-marketing
Co-promotion
Contract service
CRADA
Cross-licensing
Development
Distribution
Evaluation
Grant award
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Royalty financing
Spin out
Sub-license
Supply
Technology transfer
7.5. By therapy area
Hospital care
Cardiovascular
Central nervous system
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Hematology
Hormonal disorders
Immunology
Infection
Inflammatory
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Respiratory
Sensory organ
Animal health
7.5. By technology area/deal focus
Adjuvant
Analysis
Animal models
Assays
Biodefense
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Bioprocessing
Biosimilars/Biobetters
Blood products
Cell culture
Cell therapy
Clinical testing
Medical devices
Diagnostics
Diagnostics – companion
Discovery tools
DNA probes
Drug delivery
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Glycomics
Imaging
Implant
In vitro models
Microarray
Monoclonal antibodies
Nanotechnology
Natural product
Oligonucleotide
Orphan drug
Packaging
Pediatrics
Peptides
Personalized medicine
Pharmacogenomics
Processes
Proteomics
Radio/chemo-therapy
Rational drug design
Recombinant DNA
Regenerative medicine
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Software tools
Stem cells
Toxicity
Transgenics
Vaccines

Chapter 8 – M&A directory 2011
8.1. Introduction
8.2. By company A-Z
8.3. By industry sector
Bigpharma
Pharmaceuticals
Biotechnology
Diagnostics
Drug delivery
Medical device
Consumer health
Specialty pharma
Generic pharma
Agricultural
Animal health
Research tools
Service company

Chapter 9 – Submitting Opportunities to Potential Partners
9.1. Introduction
9.2. How to submit an opportunity
9.3. Opportunity submission template
9.4. Sending emails
9.5. Face to face at partnering events
9.6. Online submission forms
9.7. Forthcoming partnering events in 2012

Chapter 10 – Resources
Further information
Methodology
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
Order Form – Partnering Agreements Company Profiles

Table Of Figures

Figure 1: Partnering activity by volume 2007 to 2011
Figure 2: Partnering activity by deal dollars 2007 to 2011
Figure 3: Bigpharma partnering activity 2007 to 2011
Figure 4: Partnering activity by industry sector – 2011 147
Figure 5: Partnering activity by stage of development – 2011
Figure 6: Partnering activity by deal type – 2011
Figure 7: Partnering activity by therapy focus – 2011
Figure 8: Partnering deal terminations - 2011
Figure 9: M&A activity by volume 2007 to 2011
Figure 10: M&A activity by deal dollars 2007 to 2011
Figure 11: Bigpharma M&A activity 2007 to 2011
Figure 12: M&A activity by industry sector, 2011
Figure 13: Leading Bigpharma partnering companies, 2011
Figure 14: Bigpharma partnering activity – top 50 by pharma sales
Figure 15: Bigpharma partnering activity - graphic
Figure 16: Leading Bigpharma M&A companies, 2011
Figure 17: Bigpharma M&A activity – top 50 by pharma sales
Figure 18: Bigpharma M&A activity – graphic
Figure 19: Leading partnering deals by value, 2011
Figure 20: Leading M&A deals involving bigpharma by value, 2011
Figure 21: Abbott partnering activity by month – 2011
Figure 22: Abbott partnering activity by industry sector – 2011
Figure 23: Abbott partnering activity by deal type - 2011
Figure 24: Abbott partnering activity by stage of development – 2011
Figure 25: Abbott partnering acitivity by therapy area – 2011
Figure 26: Abbott partnering deals in 2011
Figure 27: Abbott M&A deals in 2011
Figure 28: Actavis partnering activity by month – 2011
Figure 29: Actavis partnering activity by industry sector – 2011
Figure 30: Actavis partnering activity by deal type - 2011
Figure 31: Actavis partnering activity by stage of development – 2011
Figure 32: Actavis partnering acitivity by therapy area – 2011
Figure 33: Actavis partnering deals in 2011
Figure 34: Actavis M&A deals in 2011
Figure 35: Alcon partnering activity by month – 2011
Figure 36: Alcon partnering activity by industry sector – 2011
Figure 37: Alcon partnering activity by deal type - 2011
Figure 38: Alcon partnering activity by stage of development – 2011
Figure 39: Alcon partnering acitivity by therapy area – 2011
Figure 40: Alcon partnering deals in 2011
Figure 41: Alcon M&A deals in 2011
Figure 42: Allergan partnering activity by month – 2011
Figure 43: Allergan partnering activity by industry sector – 2011
Figure 44: Allergan partnering activity by deal type - 2011
Figure 45: Allergan partnering activity by stage of development – 2011
Figure 46: Allergan partnering acitivity by therapy area – 2011
Figure 47: Allergan partnering deals in 2011
Figure 48: Allergan M&A deals in 2011
Figure 49: Amgen partnering activity by month – 2011
Figure 50: Amgen partnering activity by industry sector – 2011
Figure 51: Amgen partnering activity by deal type - 2011
Figure 52: Amgen partnering activity by stage of development – 2011
Figure 53: Amgen partnering acitivity by therapy area – 2011
Figure 54: Amgen partnering deals in 2011
Figure 55: Amgen M&A deals in 2011
Figure 56: Apotex partnering activity by month – 2011
Figure 57: Apotex partnering activity by industry sector – 2011
Figure 58: Apotex partnering activity by deal type - 2011
Figure 59: Apotex partnering activity by stage of development – 2011
Figure 60: Apotex partnering acitivity by therapy area – 2011
Figure 61: Apotex partnering deals in 2011
Figure 62: Apotex M&A deals in 2011
Figure 63: Astellas partnering activity by month – 2011
Figure 64: Astellas partnering activity by industry sector – 2011
Figure 65: Astellas partnering activity by deal type - 2011
Figure 66: Astellas partnering activity by stage of development – 2011
Figure 67: Astellas partnering acitivity by therapy area – 2011
Figure 68: Astellas partnering deals in 2011
Figure 69: Astellas M&A deals in 2011
Figure 70: AstraZeneca partnering activity by month – 2011
Figure 71: AstraZeneca partnering activity by industry sector – 2011
Figure 72: AstraZeneca partnering activity by deal type - 2011
Figure 73: AstraZeneca partnering activity by stage of development – 2011
Figure 74: AstraZeneca partnering acitivity by therapy area – 2011
Figure 75: AstraZeneca partnering deals in 2011
Figure 76: AstraZeneca M&A deals in 2011
Figure 77: Baxter partnering activity by month – 2011
Figure 78: Baxter partnering activity by industry sector – 2011
Figure 79: Baxter partnering activity by deal type - 2011
Figure 80: Baxter partnering activity by stage of development – 2011
Figure 81: Baxter partnering acitivity by therapy area – 2011
Figure 82: Baxter partnering deals in 2011
Figure 83: Baxter M&A deals in 2011
Figure 84: Bayer partnering activity by month – 2011
Figure 85: Bayer partnering activity by industry sector – 2011
Figure 86: Bayer partnering activity by deal type - 2011
Figure 87: Bayer partnering activity by stage of development – 2011
Figure 88: Bayer partnering acitivity by therapy area – 2011
Figure 89: Bayer partnering deals in 2011
Figure 90: Bayer M&A deals in 2011
Figure 91: Biogen Idec partnering activity by month – 2011
Figure 92: Biogen Idec partnering activity by industry sector – 2011
Figure 93: Biogen Idec partnering activity by deal type - 2011
Figure 94: Biogen Idec partnering activity by stage of development – 2011
Figure 95: Biogen Idec partnering acitivity by therapy area – 2011
Figure 96: Biogen Idec partnering deals in 2011
Figure 97: Biogen Idec M&A deals in 2011
Figure 98: Boehringer Ingelheim partnering activity by month – 2011
Figure 99: Boehringer Ingelheim partnering activity by industry sector – 2011
Figure 100: Boehringer Ingelheim partnering activity by deal type - 2011
Figure 101: Boehringer Ingelheim partnering activity by stage of development – 2011
Figure 102: Boehringer Ingelheim partnering acitivity by therapy area – 2011
Figure 103: Boehringer Ingelheim partnering deals in 2011
Figure 104: Boehringer Ingelheim M&A deals in 2011
Figure 105: Bristol-Myers Squibb partnering activity by month – 2011
Figure 106: Bristol-Myers Squibb partnering activity by industry sector – 2011
Figure 107: Bristol-Myers Squibb partnering activity by deal type - 2011
Figure 108: Bristol-Myers Squibb partnering activity by stage of development – 2011
Figure 109: Bristol-Myers Squibb partnering acitivity by therapy area – 2011
Figure 110: Bristol-Myers Squibb partnering deals in 2011
Figure 111: Bristol-Myers Squibb M&A deals in 2011
Figure 112: Celgene partnering activity by month – 2011
Figure 113: Celgene partnering activity by industry sector – 2011
Figure 114: Celgene partnering activity by deal type - 2011
Figure 115: Celgene partnering activity by stage of development – 2011
Figure 116: Celgene partnering acitivity by therapy area – 2011
Figure 117: Celgene partnering deals in 2011
Figure 118: Celgene M&A deals in 2011
Figure 119: Cephalon partnering activity by month – 2011
Figure 120: Cephalon partnering activity by industry sector – 2011
Figure 121: Cephalon partnering activity by deal type - 2011
Figure 122: Cephalon partnering activity by stage of development – 2011
Figure 123: Cephalon partnering acitivity by therapy area – 2011
Figure 124: Cephalon partnering deals in 2011
Figure 125: Cephalon M&A deals in 2011
Figure 126: Chugai partnering activity by month – 2011
Figure 127: Chugai partnering activity by industry sector – 2011
Figure 128: Chugai partnering activity by deal type - 2011
Figure 129: Chugai partnering activity by stage of development – 2011
Figure 130: Chugai partnering acitivity by therapy area – 2011
Figure 131: Chugai partnering deals in 2011
Figure 132: Chugai M&A deals in 2011
Figure 133: CSL partnering activity by month – 2011
Figure 134: CSL partnering activity by industry sector – 2011
Figure 135: CSL partnering activity by deal type - 2011
Figure 136: CSL partnering activity by stage of development – 2011
Figure 137: CSL partnering acitivity by therapy area – 2011
Figure 138: CSL partnering deals in 2011
Figure 139: CSL M&A deals in 2011
Figure 140: Daiichi Sankyo partnering activity by month – 2011
Figure 141: Daiichi Sankyo partnering activity by industry sector – 2011
Figure 142: Daiichi Sankyo partnering activity by deal type - 2011
Figure 143: Daiichi Sankyo partnering activity by stage of development – 2011
Figure 144: Daiichi Sankyo partnering acitivity by therapy area – 2011
Figure 145: Daiichi Sankyo partnering deals in 2011
Figure 146: Daiichi Sankyo M&A deals in 2011
Figure 147: Dainippon Sumitomo partnering activity by month – 2011
Figure 148: Dainippon Sumitomo partnering activity by industry sector – 2011
Figure 149: Dainippon Sumitomo partnering activity by deal type - 2011
Figure 150: Dainippon Sumitomo partnering activity by stage of development – 2011
Figure 151: Dainippon Sumitomo partnering acitivity by therapy area – 2011
Figure 152: Dainippon Sumitomo partnering deals in 2011
Figure 153: Dainippon Sumitomo M&A deals in 2011
Figure 154: Eisai partnering activity by month – 2011
Figure 155: Eisai partnering activity by industry sector – 2011
Figure 156: Eisai partnering activity by deal type - 2011
Figure 157: Eisai partnering activity by stage of development – 2011
Figure 158: Eisai partnering acitivity by therapy area – 2011
Figure 159: Eisai partnering deals in 2011
Figure 160: Eisai M&A deals in 2011
Figure 161: Eli Lilly partnering activity by month – 2011
Figure 162: Eli Lilly partnering activity by industry sector – 2011
Figure 163: Eli Lilly partnering activity by deal type – 2011
Figure 164: Eli Lilly partnering activity by stage of development – 2011
Figure 165: Eli Lilly partnering acitivity by therapy area – 2011
Figure 166: Eli Lilly partnering deals in 2011
Figure 167: Eli Lilly M&A deals in 2011
Figure 168: Forest partnering activity by month – 2011
Figure 169: Forest partnering activity by industry sector – 2011
Figure 170: Forest partnering activity by deal type - 2011
Figure 171: Forest partnering activity by stage of development – 2011
Figure 172: Forest partnering acitivity by therapy area – 2011
Figure 173: Forest partnering deals in 2011
Figure 174: Forest M&A deals in 2011
Figure 175: Genzyme partnering activity by month – 2011
Figure 176: Genzyme partnering activity by industry sector – 2011
Figure 177: Genzyme partnering activity by deal type - 2011
Figure 178: Genzyme partnering activity by stage of development – 2011
Figure 179: Genzyme partnering acitivity by therapy area – 2011
Figure 180: Genzyme partnering deals in 2011
Figure 181: Genzyme M&A deals in 2011
Figure 182: Gilead Sciences partnering activity by month – 2011
Figure 183: Gilead Sciences partnering activity by industry sector – 2011
Figure 184: Gilead Sciences partnering activity by deal type - 2011
Figure 185: Gilead Sciences partnering activity by stage of development – 2011
Figure 186: Gilead Sciences partnering acitivity by therapy area – 2011
Figure 187: Gilead Sciences partnering deals in 2011
Figure 188: Gilead Sciences M&A deals in 2011
Figure 189: GlaxoSmithKline partnering activity by month – 2011
Figure 190: GlaxoSmithKline partnering activity by industry sector – 2011
Figure 191: GlaxoSmithKline partnering activity by deal type - 2011
Figure 192: GlaxoSmithKline partnering activity by stage of development – 2011
Figure 193: GlaxoSmithKline partnering acitivity by therapy area – 2011
Figure 194: GlaxoSmithKline partnering deals in 2011
Figure 195: GlaxoSmithKline M&A deals in 2011
Figure 196: Hospira partnering activity by month – 2011
Figure 197: Hospira partnering activity by industry sector – 2011
Figure 198: Hospira partnering activity by deal type - 2011
Figure 199: Hospira partnering activity by stage of development – 2011
Figure 200: Hospira partnering acitivity by therapy area – 2011
Figure 201: Hospira partnering deals in 2011
Figure 202: Hospira M&A deals in 2011
Figure 203: Johnson & Johnson partnering activity by month – 2007-11
Figure 204: Johnson & Johnson partnering activity by industry sector – 2011
Figure 205: Johnson & Johnson partnering activity by deal type - 2011
Figure 206: Johnson & Johnson partnering activity by stage of development – 2011
Figure 207: Johnson & Johnson partnering acitivity by therapy area – 2011
Figure 208: Johnson & Johnson partnering deals in 2011
Figure 209: Johnson & Johnson M&A deals in 2011
Figure 210: Janssen partnering activity by month – 2007-11
Figure 211: Janssen partnering activity by industry sector – 2011
Figure 212: Janssen partnering activity by deal type - 2011
Figure 213: Janssen partnering activity by stage of development – 2011
Figure 214: Janssen partnering acitivity by therapy area – 2011
Figure 215: Janssen partnering deals in 2011
Figure 216: Janssen M&A deals in 2011
Figure 217: Kyowa Hakko Kirin partnering activity by month – 2011
Figure 218: Kyowa Hakko Kirin partnering activity by industry sector – 2011
Figure 219: Kyowa Hakko Kirin partnering activity by deal type - 2011
Figure 220: Kyowa Hakko Kirin partnering activity by stage of development – 2011
Figure 221: Kyowa Hakko Kirin partnering acitivity by therapy area – 2011
Figure 222: Kyowa Hakko Kirin partnering deals in 2011
Figure 223: Kyowa Hakko Kirin M&A deals in 2011
Figure 224: Lundbeck partnering activity by month – 2011
Figure 225: Lundbeck partnering activity by industry sector – 2011
Figure 226: Lundbeck partnering activity by deal type - 2011
Figure 227: Lundbeck partnering activity by stage of development – 2011
Figure 228: Lundbeck partnering acitivity by therapy area – 2011
Figure 229: Lundbeck partnering deals in 2011
Figure 230: Lundbeck M&A deals in 2011
Figure 231: Menarini partnering activity by month – 2011
Figure 232: Menarini partnering activity by industry sector – 2011
Figure 233: Menarini partnering activity by deal type - 2011
Figure 234: Menarini partnering activity by stage of development – 2011
Figure 235: Menarini partnering acitivity by therapy area – 2011
Figure 236: Menarini partnering deals in 2011
Figure 237: Menarini M&A deals in 2011
Figure 238: Merck & Co partnering activity by month – 2011
Figure 239: Merck & Co partnering activity by industry sector – 2011
Figure 240: Merck & Co partnering activity by deal type - 2011
Figure 241: Merck & Co partnering activity by stage of development – 2011
Figure 242: Merck & Co partnering acitivity by therapy area – 2011
Figure 243: Merck & Co partnering deals in 2011
Figure 244: Merck & Co M&A deals in 2011
Figure 245: Merck KGaA partnering activity by month – 2011
Figure 246: Merck KGaA partnering activity by industry sector – 2011
Figure 247: Merck KGaA partnering activity by deal type - 2011
Figure 248: Merck KGaA partnering activity by stage of development – 2011
Figure 249: Merck KGaA partnering acitivity by therapy area – 2011
Figure 250: Merck KGaA partnering deals in 2011
Figure 251: Merck KGaA M&A deals in 2011
Figure 252: Mitsubishi Tanabe partnering activity by month – 2011
Figure 253: Mitsubishi Tanabe partnering activity by industry sector – 2011
Figure 254: Mitsubishi Tanabe partnering activity by deal type - 2011
Figure 255: Mitsubishi Tanabe partnering activity by stage of development – 2011
Figure 256: Mitsubishi Tanabe partnering acitivity by therapy area – 2011
Figure 257: Mitsubishi Tanabe partnering deals in 2011
Figure 258: Mitsubishi Tanabe M&A deals in 2011
Figure 259: Mylan partnering activity by month – 2011
Figure 260: Mylan partnering activity by industry sector – 2011
Figure 261: Mylan partnering activity by deal type - 2011
Figure 262: Mylan partnering activity by stage of development – 2011
Figure 263: Mylan partnering acitivity by therapy area – 2011
Figure 264: Mylan partnering deals in 2011
Figure 265: Mylan M&A deals in 2011
Figure 266: Novartis partnering activity by month – 2011
Figure 267: Novartis partnering activity by industry sector – 2011
Figure 268: Novartis partnering activity by deal type - 2011
Figure 269: Novartis partnering activity by stage of development – 2011
Figure 270: Novartis partnering acitivity by therapy area – 2011
Figure 271: Novartis partnering deals in 2011
Figure 272: Novartis M&A deals in 2011
Figure 273: Novo Nordisk partnering activity by month – 2011
Figure 274: Novo Nordisk partnering activity by industry sector – 2011
Figure 275: Novo Nordisk partnering activity by deal type - 2011
Figure 276: Novo Nordisk partnering activity by stage of development – 2011
Figure 277: Novo Nordisk partnering acitivity by therapy area – 2011
Figure 278: Novo Nordisk partnering deals in 2011
Figure 279: Novo Nordisk M&A deals in 2011
Figure 280: Nycomed partnering activity by month – 2011
Figure 281: Nycomed partnering activity by industry sector – 2011
Figure 282: Nycomed partnering activity by deal type - 2011
Figure 283: Nycomed partnering activity by stage of development – 2011
Figure 284: Nycomed partnering acitivity by therapy area – 2011
Figure 285: Nycomed partnering deals in 2011
Figure 286: Nycomed M&A deals in 2011
Figure 287: Otsuka partnering activity by month – 2011
Figure 288: Otsuka partnering activity by industry sector – 2011
Figure 289: Otsuka partnering activity by deal type - 2011
Figure 290: Otsuka partnering activity by stage of development – 2011
Figure 291: Otsuka partnering acitivity by therapy area – 2011
Figure 292: Otsuka partnering deals in 2011
Figure 293: Otsuka M&A deals in 2011
Figure 294: Pfizer partnering activity by month – 2011
Figure 295: Pfizer partnering activity by industry sector – 2011
Figure 296: Pfizer partnering activity by deal type - 2011
Figure 297: Pfizer partnering activity by stage of development – 2011
Figure 298: Pfizer partnering acitivity by therapy area – 2011
Figure 299: Pfizer partnering deals in 2011
Figure 300: Pfizer M&A deals in 2011
Figure 301: Roche partnering activity by month – 2011
Figure 302: Roche partnering activity by industry sector – 2011
Figure 303: Roche partnering activity by deal type - 2011
Figure 304: Roche partnering activity by stage of development – 2011
Figure 305: Roche partnering acitivity by therapy area – 2011
Figure 306: Roche partnering deals in 2011
Figure 307: Roche M&A deals in 2011
Figure 308: Sanofi partnering activity by month – 2011
Figure 309: Sanofi partnering activity by industry sector – 2011
Figure 310: Sanofi partnering activity by deal type - 2011
Figure 311: Sanofi partnering activity by stage of development – 2011
Figure 312: Sanofi partnering acitivity by therapy area – 2011
Figure 313: Sanofi partnering deals in 2011
Figure 314: Sanofi M&A deals in 2011
Figure 315: Servier partnering activity by month – 2011
Figure 316: Servier partnering activity by industry sector – 2011
Figure 317: Servier partnering activity by deal type - 2011
Figure 318: Servier partnering activity by stage of development – 2011
Figure 319: Servier partnering acitivity by therapy area – 2011
Figure 320: Servier partnering deals in 2011
Figure 321: Servier M&A deals in 2011
Figure 322: Shionogi partnering activity by month – 2011
Figure 323: Shionogi partnering activity by industry sector – 2011
Figure 324: Shionogi partnering activity by deal type - 2011
Figure 325: Shionogi partnering activity by stage of development – 2011
Figure 326: Shionogi partnering acitivity by therapy area – 2011
Figure 327: Shionogi partnering deals in 2011
Figure 328: Shionogi M&A deals in 2011
Figure 329: Shire partnering activity by month – 2011
Figure 330: Shire partnering activity by industry sector – 2011
Figure 331: Shire partnering activity by deal type - 2011
Figure 332: Shire partnering activity by stage of development – 2011
Figure 333: Shire partnering acitivity by therapy area – 2011
Figure 334: Shire partnering deals in 2011
Figure 335: Shire M&A deals in 2011
Figure 336: Stada partnering activity by month – 2011
Figure 337: Stada partnering activity by industry sector – 2011
Figure 338: Stada partnering activity by deal type - 2011
Figure 339: Stada partnering activity by stage of development – 2011
Figure 340: Stada partnering acitivity by therapy area – 2011
Figure 341: Stada partnering deals in 2011
Figure 342: Stada M&A deals in 2011
Figure 343: Takeda partnering activity by month – 2011
Figure 344: Takeda partnering activity by industry sector – 2011
Figure 345: Takeda partnering activity by deal type - 2011
Figure 346: Takeda partnering activity by stage of development – 2011
Figure 347: Takeda partnering acitivity by therapy area – 2011
Figure 348: Takeda partnering deals in 2011
Figure 349: Takeda M&A deals in 2011
Figure 350: Teva partnering activity by month – 2011
Figure 351: Teva partnering activity by industry sector – 2011
Figure 352: Teva partnering activity by deal type - 2011
Figure 353: Teva partnering activity by stage of development – 2011
Figure 354: Teva partnering acitivity by therapy area – 2011
Figure 355: Teva partnering deals in 2011
Figure 356: Teva M&A deals in 2011
Figure 357: UCB partnering activity by month – 2011
Figure 358: UCB partnering activity by industry sector – 2011
Figure 359: UCB partnering activity by deal type - 2011
Figure 360: UCB partnering activity by stage of development – 2011
Figure 361: UCB partnering acitivity by therapy area – 2011
Figure 362: UCB partnering deals in 2011
Figure 363: UCB M&A deals in 2011
Figure 364: Warner Chilcott partnering activity by month – 2011
Figure 365: Warner Chilcott partnering activity by industry sector – 2011
Figure 366: Warner Chilcott partnering activity by deal type - 2011
Figure 367: Warner Chilcott partnering activity by stage of development – 2011
Figure 368: Warner Chilcott partnering acitivity by therapy area – 2011
Figure 369: Warner Chilcott partnering deals in 2011
Figure 370: Warner Chilcott M&A deals in 2011
Figure 371: Watson partnering activity by month – 2011
Figure 372: Watson partnering activity by industry sector – 2011
Figure 373: Watson partnering activity by deal type - 2011
Figure 374: Watson partnering activity by stage of development – 2011
Figure 375: Watson partnering acitivity by therapy area – 2011
Figure 376: Watson partnering deals in 2011
Figure 377: Watson M&A deals in 2011
Figure 378: Partnering deals by industry sector – 2011
Figure 379: Deals by stage of development – 2011
Figure 380: Discovery stage deals by deal type - 2011
Figure 381: Pre-clinical stage deals by deal type - 2011
Figure 382: Phase I stage deals by deal type - 2011
Figure 383: Phase II stage deals by deal type - 2011
Figure 384: Phase III stage deals by deal type - 2011
Figure 385: Registration stage deals by deal type - 2011
Figure 386: Market stage deals by deal type - 2011
Figure 387: Deals by deal type – 2011
Figure 388: Asset purchase deals by stage of development - 2011
Figure 389: Assignment deals by stage of development - 2011
Figure 390: Bigpharma outlicensing deals by stage of development - 2011
Figure 391: Collaborative R&D deals by stage of development - 2011
Figure 392: Co-development deals by stage of development - 2011
Figure 393: Co-marketing deals by stage of development - 2011
Figure 394: Co-promotion deals by stage of development - 2011
Figure 395: Contract service deals by stage of development - 2011
Figure 396: CRADA deals by stage of development - 2011
Figure 397: Cross-licensing deals by stage of development - 2011
Figure 398: Development deals by stage of development - 2011
Figure 399: Distribution deals by stage of development - 2011
Figure 400: Evaluation deals by stage of development - 2011
Figure 401: Grant award deals by stage of development - 2011
Figure 402: Joint venture deals by stage of development - 2011
Figure 403: Licensing deals by stage of development - 2011
Figure 404: Manufacturing deals by stage of development - 2011
Figure 405: Marketing deals by stage of development - 2011
Figure 406: Option deals by stage of development - 2011
Figure 407: Promotion deals by stage of development - 2011
Figure 408: Research deals by stage of development - 2011
Figure 409: Royalty financing deals by stage of development - 2011
Figure 410: Spin out deals by stage of development - 2011
Figure 411: Sub-license deals by stage of development - 2011
Figure 412: Supply deals by stage of development - 2011
Figure 413: Technology transfer deals by stage of development - 2011
Figure 414: Hospital care deals by stage of development - 2011
Figure 415: Hospital care deals by therapeutic target - 2011
Figure 416: Hospital care deals by stage of development - 2011
Figure 417: Hospital care deals by therapeutic target - 2011
Figure 418: CNS deals by stage of development - 2011
Figure 419: CNS deals by therapeutic target - 2011
Figure 420: Dental deals by stage of development - 2011
Figure 421: Dental deals by therapeutic target - 2011
Figure 422: Dermatology deals by stage of development - 2011
Figure 423: Dermatology deals by therapeutic target - 2011
Figure 424: Gastrointestinal deals by stage of development - 2011
Figure 425: Gastrointestinal deals by therapeutic target - 2011
Figure 426: Genetic disorders deals by stage of development - 2011
Figure 427: Genetic disorders deals by therapeutic target - 2011
Figure 428: Genitourinary deals by stage of development - 2011
Figure 429: Genitourinary deals by therapeutic target - 2011
Figure 430: Hematology deals by stage of development - 2011
Figure 431: Hematology deals by therapeutic target - 2011
Figure 432: Hormonal disorder deals by stage of development - 2011
Figure 433: Hormonal disorder deals by therapeutic target - 2011
Figure 434: Immunology deals by stage of development - 2011
Figure 435: Immunology deals by therapeutic target - 2011
Figure 436: Infection deals by stage of development - 2011
Figure 437: Infection deals by therapeutic target - 2011
Figure 438: Inflammatory deals by stage of development - 2011
Figure 439: Inflammatory deals by therapeutic target - 2011
Figure 440: Metabolic deals by stage of development - 2011
Figure 441: Metabolic deals by therapeutic target - 2011
Figure 442: Musculoskeletal deals by stage of development - 2011
Figure 443: Musculoskeletal deals by therapeutic target - 2011
Figure 444: Oncology deals by stage of development - 2011
Figure 445: Oncology deals by therapeutic target - 2011
Figure 446: Ophthalmics deals by stage of development - 2011
Figure 447: Ophthalmics deals by therapeutic target - 2011
Figure 448: Respiratory deals by stage of development - 2011
Figure 449: Respiratory deals by therapeutic target - 2011
Figure 450: Sensory organ deals by stage of development - 2011
Figure 451: Sensory organ deals by therapeutic target - 2011
Figure 452: Animal health deals by stage of development - 2011
Figure 453: Deals by technology area/focus area – 2011
Figure 454: Adjuvant deals by stage of development - 2011
Figure 455: Analysis deals by stage of development - 2011
Figure 456: Animal model deals by stage of development - 2011
Figure 457: Assay deals by stage of development - 2011
Figure 458: Biodefense deals by stage of development - 2011
Figure 459: Bioinformatics deals by stage of development - 2011
Figure 460: Biological compound deals by stage of development - 2011
Figure 461: Biomarker deals by stage of development - 2011
Figure 462: Biomaterial deals by stage of development - 2011
Figure 463: Bioprocessing deals by stage of development - 2011
Figure 464: Biosimilar/biobetter deals by stage of development - 2011
Figure 465: Blood product deals by stage of development - 2011
Figure 466: Cell culture deals by stage of development - 2011
Figure 467: Cell therapy deals by stage of development - 2011
Figure 468: Clinical testing deals by stage of development - 2011
Figure 469: Medical device deals by stage of development - 2011
Figure 470: Diagnostic deals by stage of development - 2011
Figure 471: Companion diagnostic deals by stage of development - 2011
Figure 472: Discovery tool deals by stage of development - 2011
Figure 473: DNA probe deals by stage of development - 2011
Figure 474: Drug delivery deals by stage of development - 2011
Figure 475: Epigenetic deals by stage of development - 2011
Figure 476: Equipment deals by stage of development - 2011
Figure 477: Facility deals by stage of development - 2011
Figure 478: Gene therapy deals by stage of development - 2011
Figure 479: Genomic deals by stage of development - 2011
Figure 480: Glycomic deals by stage of development - 2011
Figure 481: Imaging deals by stage of development - 2011
Figure 482: Implant deals by stage of development - 2011
Figure 483: In vitro model deals by stage of development - 2011
Figure 484: Microarray deals by stage of development - 2011
Figure 485: Monoclonal antibody deals by stage of development - 2011
Figure 486: Nanotechnology deals by stage of development - 2011
Figure 487: Natural product deals by stage of development - 2011
Figure 488: Oligonucleotide deals by stage of development - 2011
Figure 489: Orphan drug deals by stage of development - 2011
Figure 490: Packaging deals by stage of development - 2011
Figure 491: Pediatric deals by stage of development - 2011
Figure 492: Peptide deals by stage of development - 2011
Figure 493: Personalized medicine deals by stage of development - 2011
Figure 494: Pharmacogenomic deals by stage of development - 2011
Figure 495: Process deals by stage of development - 2011
Figure 496: Proteomic deals by stage of development - 2011
Figure 497: Radio/chemo-therapy deals by stage of development - 2011
Figure 498: Rational drug design deals by stage of development - 2011
Figure 499: Recombinant DNA deals by stage of development - 2011
Figure 500: Regenerative medicine deals by stage of development - 2011
Figure 501: Research service deals by stage of development - 2011
Figure 502: Research supply deals by stage of development - 2011
Figure 503: RNA therapeutics deals by stage of development - 2011
Figure 504: Screening deals by stage of development - 2011
Figure 505: Small molecule deals by stage of development - 2011
Figure 506: Software tool deals by stage of development - 2011
Figure 507: Stem cell deals by stage of development - 2011
Figure 508: Toxicity deals by stage of development - 2011
Figure 509: Transgenic deals by stage of development - 2011
Figure 510: Vaccine deals by stage of development - 2011
Figure 511: M&A deals by industry sector – 2011
Figure 512: Typical partnering opportunity submission template
Figure 513: Online partnering resources